NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Carlsmed CARL

Carlsmed listed on Nasdaq on 24 Jul 2025 and is not in the S&P 500. It is worth $472 million. Its board has 8 directors, 5 of them independent. 4 other officers are on file.

Chair and CEO
Michael Cordonnier
Listed
24 Jul 2025 on Nasdaq
Headquarters
Carlsbad, CA
Market cap
$472M
19 Nov 2026 close
Revenue
$51M
Fiscal year 2025
Price to sales
9.3
Market cap over revenue

Financials

Financial history

Twelve months to 30 Sep 2026, from Carlsmed's quarterly filings.

Quarters since Jun 2024

Revenue
$72M
Up 60% on the year before
Net income
$-40M
-55.8% of revenue
Free cash flow
$-35M
Operating cash flow less capital spending
P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jun 2024 to Sep 2026

$0$10M$20M$30M202420252026$22M

Carlsmed's market cap since July 2025

Weekly, up to 13 Nov 2026

Sep 2025NovJan 2026MarMayJulSepNov$470M

Board and leadership

Board and officers

Board from the proxy filed 22 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (8)
Michael CordonnierChair; CEO, PresidentNot independent · since 2018Chair; CEO, President2018No50
Niall CaseyChief IP OfficerNot independent · since 2018Chief IP Officer2018No50
Robert Mittendorff, M.D., M.B.A.DirectorIndependent · since 2022 · Compensation, Nominating and Corporate GovernanceGeneral Partner and Head of Healthcare, B Capital GroupDirector2022YesCompensation, Nominating and Corporate Governance49
Kevin O'BoyleDirectorIndependent · since 2024 · Audit (chair), CompensationExecutive management professional in the medical device industryDirector2024YesAudit (chair), Compensation70
Kevin C. OboyleDirectorDirector
Jonathan D. RootDirectorIndependent · since 2020 · Nominating and Corporate Governance (chair)Managing Member, Presidio Management Group X, LLC and U.S. Venture Partners fundsOther boards: Omada Health and Edgewise TherapeuticsDirector2020YesNominating and Corporate Governance (chair)66
Kevin SidowLead Independent DirectorIndependent · since 2020 · Audit, Compensation (chair), Nominating and Corporate GovernanceFormer President and Chief Executive Officer, Moximed, Inc.Lead Independent Director2020YesAudit, Compensation (chair), Nominating and Corporate Governance68
Philip M. YoungDirectorIndependent · since 2020 · AuditSenior Advisor, U.S. Venture PartnersDirector2020YesAudit86
Officers (4)
Richard HeppenstallCFO, TreasurerLast filed 30 Sep 2026CFO, Treasurer
Jeffrey BertoliniChief Operating OfficerLast filed 10 Sep 2026Chief Operating Officer
William Scott DurallChief Commercial OfficerLast filed 30 Jan 2026Chief Commercial Officer
Jennifer KamocsayChief Legal OfficerLast filed 30 Sep 2026Chief Legal Officer

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $2.7 million of stock in 5 sales and made no open-market purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
3 Nov 2026SaleJeffrey BertoliniChief Operating OfficerChief Operating OfficerSale747$11K
30 Oct 2026SaleJeffrey BertoliniChief Operating OfficerChief Operating OfficerSale243$4K
5 Oct 2026SaleJeffrey BertoliniChief Operating OfficerChief Operating OfficerSale747$11K
30 Sep 2026SaleJeffrey BertoliniChief Operating OfficerChief Operating OfficerSale243$3K
2 Mar 2026SaleMichael CordonnierCEO, PresidentCEO, PresidentSale197,855$2.6M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 2 appointments of directors and officers and 1 large insider sale in the last two years.

Left the company or board 1Appointed 2WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Carlsmed's insider sales.

Events, newest first

Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.